

Nikolas Herold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2140144/publications.pdf>

Version: 2024-02-01

30
papers

805
citations

623734

14
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

1275
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6885.	4.1	156
2	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. <i>Nature Medicine</i> , 2017, 23, 256-263.	30.7	102
3	Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. <i>Cancers</i> , 2018, 10, 240.	3.7	80
4	HIV-1 Entry in SupT1-R5, CEM-ss, and Primary CD4 ⁺ T Cells Occurs at the Plasma Membrane and Does Not Require Endocytosis. <i>Journal of Virology</i> , 2014, 88, 13956-13970.	3.4	58
5	SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. <i>Cell Cycle</i> , 2017, 16, 1029-1038.	2.6	56
6	With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. <i>Experimental Hematology</i> , 2017, 52, 32-39.	0.4	43
7	Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. <i>Journal of Virology</i> , 2016, 90, 7469-7480.	3.4	40
8	A quantitative measure for alterations in the actin cytoskeleton investigated with automated high-throughput microscopy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 52-63.	1.5	38
9	Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. <i>EMBO Molecular Medicine</i> , 2020, 12, e10419.	6.9	35
10	Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 3693-3704.	3.7	32
11	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. <i>Blood Cancer Journal</i> , 2018, 8, 98.	6.2	28
12	The Nucleocapsid Domain of Gag Is Dispensable for Actin Incorporation into HIV-1 and for Association of Viral Budding Sites with Cortical F-Actin. <i>Journal of Virology</i> , 2014, 88, 7893-7903.	3.4	23
13	Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	18
14	Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. <i>International Journal of Oncology</i> , 2021, 58, 211-225.	3.3	16
15	SAMHD1 is a barrier to antimetabolite-based cancer therapies. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1287554.	0.7	13
16	Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 488-496.	2.5	12
17	Reply to "Can HIV-1 Entry Sites Be Deduced by Comparing Bulk Endocytosis to Functional Readouts for Viral Fusion?". <i>Journal of Virology</i> , 2015, 89, 2986-2987.	3.4	11
18	Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. <i>British Journal of Haematology</i> , 2022, 196, 248-254.	2.5	9

#	ARTICLE	IF	CITATIONS
19	Improved Local Control by Extensive Surgery in High-Risk Neuroblastoma May Be Dependent on Adjuvant Radiotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1965-1966.	1.6	7
20	Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2 β . <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 7-11.	5.0	6
21	The Early Bird Catches the Worm - Can Evolution Teach us Lessons in Fighting HIV?. <i>Current HIV Research</i> , 2016, 14, 183-210.	0.5	5
22	A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of ¹⁷⁷ Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma – LuDO-N. <i>Frontiers in Pediatrics</i> , 2022, 10, 836230.	1.9	5
23	Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3664.	4.1	4
24	Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas. <i>Cancers</i> , 2022, 14, 1186.	3.7	4
25	Evidence for SAMHD1 Tumor Suppressor Functions in Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2020, 143, 7-8.	1.4	1
26	Overexpression of the Interferon-Inducible Isoform 4 of NCOA7 Dissects the Entry Route of Enveloped Viruses and Demonstrates that HIV Enters Cells via Fusion at the Plasma Membrane. <i>Viruses</i> , 2019, 11, 121.	3.3	1
27	The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL). <i>Blood</i> , 2018, 132, 4130-4130.	1.4	1
28	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 655-666.	2.8	1
29	A small leak will sink a great ship: HIV – host interactions. , 2016, , 25-42.		0
30	Abstract P3-08-07: Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer. , 2020, , .		0